Royal Bank Of Canada Paratek Pharmaceuticals, Inc. Transaction History

Royal Bank Of Canada

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$1.52 - $2.8 $6,499 - $11,972	4,276 Added 855.2%	4,776 $10,000
Q1 2023 May 15, 2023	SELL	$1.37 - $2.54 $568 - $1,054	-415 Reduced 45.36%	500 $1,000
Q4 2022 Feb 14, 2023	SELL	$1.67 - $2.51 $501 - $752	-300 Reduced 24.69%	915 $1,000
Q3 2022 Nov 14, 2022	BUY	$1.96 - $2.93 $1,401 - $2,094	715 Added 143.0%	1,215 $3,000
Q2 2022 Aug 15, 2022	SELL	$1.73 - $3.09 $5,200 - $9,288	-3,006 Reduced 85.74%	500 $1,000
Q1 2022 May 16, 2022	SELL	$2.94 - $4.77 $25,239 - $40,950	-8,585 Reduced 71.0%	3,506 $10,000
Q4 2021 Feb 14, 2022	BUY	$4.07 - $5.3 $27,098 - $35,287	6,658 Added 122.55%	12,091 $54,000
Q3 2021 Nov 15, 2021	BUY	$4.7 - $7.24 $8,455 - $13,024	1,799 Added 49.5%	5,433 $26,000
Q2 2021 Aug 16, 2021	BUY	$6.81 - $10.93 $24,747 - $39,719	3,634 New	3,634 $24,000

1.54M

Ticker PRTK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,862,500
Description
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectru...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.